A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL.
The file type is application/pdf
.
HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs?
2013
Molecular Neurodegeneration
Histone deacetylase (HDAC) inhibitors have been demonstrated to be beneficial in animal models of neurodegenerative diseases. Such results were mainly associated with the epigenetic modulation caused by HDACs, especially those from class I, via chromatin deacetylation. However, other mechanisms may contribute to the neuroprotective effect of HDAC inhibitors, since each HDAC may present distinct specific functions within the neurodegenerative cascades. Such an example is HDAC6 for which the role
doi:10.1186/1750-1326-8-7
pmid:23356410
pmcid:PMC3615964
fatcat:kugxp4okmjf6pgecwo3vfyapsm